Brief: Newron Presents Six-Month Interim Data From The First 100 Patients Randomized In Study 014/015 At The 31St European Congress Of Psychiatry
28/03/2023 15:25
Newron Pharmaceuticals SpA NWRN.S :
* NEWRON PRESENTS SIX-MONTH INTERIM DATA FROM THE FIRST 100
PATIENTS RANDOMIZED IN STUDY 014/015 AT THE 31ST EUROPEAN
CONGRESS OF PSYCHIATRY
* NEWRON PHARMACEUTICALS SPA-STUDY 014/015 IS A PHASE II
TRIAL
EVALUATING EVENAMIDE AS ADD-ON THERAPY FOR PATIENTS WITH
TREATMENT-RESISTANT SCHIZOPHRENIA
Source text for Eikon: ID:nBw4lZD2ha
Further company coverage: NWRN.S
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study